PMC:7600245 / 22755-24579
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T100 | 224-227 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T81 | 52-61 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
| T82 | 123-132 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
| T83 | 427-432 | Disease | denotes | Ebola | http://purl.obolibrary.org/obo/MONDO_0005737 |
| T84 | 530-538 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T85 | 718-726 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T86 | 729-738 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T87 | 931-939 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T88 | 940-949 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T89 | 1250-1265 | Disease | denotes | virus infection | http://purl.obolibrary.org/obo/MONDO_0005108 |
| T90 | 1256-1265 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T91 | 1368-1376 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T92 | 1377-1386 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T93 | 1572-1580 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T94 | 1581-1590 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T95 | 1766-1774 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T212 | 62-69 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
| T213 | 177-185 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T214 | 202-209 | http://purl.obolibrary.org/obo/NCBITaxon_33208 | denotes | animals |
| T215 | 228-235 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
| T216 | 307-309 | http://purl.obolibrary.org/obo/CLO_0054055 | denotes | 71 |
| T217 | 399-400 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T218 | 410-418 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T219 | 452-453 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T220 | 481-486 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T221 | 856-861 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T222 | 1097-1098 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T223 | 1147-1148 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T224 | 1188-1189 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T225 | 1217-1225 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
| T226 | 1250-1255 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T227 | 1391-1393 | http://purl.obolibrary.org/obo/CLO_0054055 | denotes | 71 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T315 | 133-138 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T316 | 167-176 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T317 | 365-376 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T318 | 481-486 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T319 | 551-562 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T320 | 664-667 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T321 | 798-817 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T322 | 798-807 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T323 | 808-817 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T324 | 823-826 | Chemical | denotes | INF | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T325 | 856-861 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T326 | 973-984 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T327 | 1157-1162 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T328 | 1176-1186 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T329 | 1200-1209 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T330 | 1402-1413 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T331 | 1464-1474 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T332 | 1639-1650 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T333 | 1697-1708 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T334 | 1710-1728 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T335 | 1733-1744 | Chemical | denotes | oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T44 | 1217-1232 | http://purl.obolibrary.org/obo/GO_0061025 | denotes | membrane fusion |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T12 | 940-949 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T13 | 1377-1386 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T14 | 1581-1590 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T169 | 0-139 | Sentence | denotes | Favipiravir is effective against several strains of influenza viruses, including those that are resistant to existing anti-influenza drugs. |
| T170 | 140-311 | Sentence | denotes | Favipiravir also showed an antiviral activity in experimental animals against other RNA viruses, including arenaviruses, alphaviruses, bunyaviruses, and flaviviruses [71]. |
| T171 | 312-438 | Sentence | denotes | Furthermore, preliminary results also indicated that favipiravir potentially possesses a moderate activity against Ebola [72]. |
| T172 | 439-834 | Sentence | denotes | Importantly, a recent nonrandomized, open-label study in patients (n = 80) with non-severe COVID-19 showed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for thirteen days) with INF-α had significantly better therapeutic effects on SARS-CoV-2 infection, in terms of disease progression and viral clearance, than lopinavir/ritonavir with INF-α [73]. |
| T173 | 835-1308 | Sentence | denotes | Furthermore, an open-label, prospective, randomized, multicenter study in adults (n = 236) with COVID-19 pneumonia in China revealed that favipiravir (1600 mg orally twice daily on the first day, then 600 mg orally twice daily for 7–10 days) was associated with a higher 7-day clinical recovery rate compared to a control group treated with umifenovir, a potential inhibitor of the membrane fusion stage during the virus infection, (200 mg three times daily for 7–10 days). |
| T174 | 1309-1492 | Sentence | denotes | The 7-day clinical recovery rate in patients with moderate COVID-19 pneumonia was 71% in the favipiravir-treated patients, whereas the rate was 56% in the umifenovir-treated patients. |
| T175 | 1493-1627 | Sentence | denotes | Likewise, the 7-day clinical recovery rate in patients with severe to critical COVID-19 pneumonia was 6% versus 0%, respectively [74]. |
| T176 | 1628-1824 | Sentence | denotes | Currently, favipiravir is being studied alone or in combination with tocilizumab, hydroxychloroquine, or oseltamivir for the treatment of COVID-19 in more than 23 clinical trials across the world. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 638 | 664-669 | Gene | denotes | INF-α | Gene:3451 |
| 639 | 823-828 | Gene | denotes | INF-α | Gene:3451 |
| 640 | 52-69 | Species | denotes | influenza viruses | Tax:11308 |
| 641 | 427-432 | Species | denotes | Ebola | Tax:1570291 |
| 642 | 496-504 | Species | denotes | patients | Tax:9606 |
| 643 | 1345-1353 | Species | denotes | patients | Tax:9606 |
| 644 | 1422-1430 | Species | denotes | patients | Tax:9606 |
| 645 | 1483-1491 | Species | denotes | patients | Tax:9606 |
| 646 | 1539-1547 | Species | denotes | patients | Tax:9606 |
| 647 | 123-132 | Species | denotes | influenza | Tax:11520 |
| 648 | 0-11 | Chemical | denotes | Favipiravir | MESH:C462182 |
| 649 | 140-151 | Chemical | denotes | Favipiravir | MESH:C462182 |
| 650 | 365-376 | Chemical | denotes | favipiravir | MESH:C462182 |
| 651 | 551-562 | Chemical | denotes | favipiravir | MESH:C462182 |
| 652 | 798-817 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 653 | 973-984 | Chemical | denotes | favipiravir | MESH:C462182 |
| 654 | 1176-1186 | Chemical | denotes | umifenovir | MESH:C086979 |
| 655 | 1402-1413 | Chemical | denotes | favipiravir | MESH:C462182 |
| 656 | 1464-1474 | Chemical | denotes | umifenovir | MESH:C086979 |
| 657 | 1639-1650 | Chemical | denotes | favipiravir | MESH:C462182 |
| 658 | 1697-1708 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 659 | 1710-1728 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 660 | 1733-1744 | Chemical | denotes | oseltamivir | MESH:D053139 |
| 661 | 530-538 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 662 | 723-738 | Disease | denotes | CoV-2 infection | MESH:C000657245 |
| 663 | 931-949 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 664 | 1250-1265 | Disease | denotes | virus infection | MESH:D001102 |
| 665 | 1368-1386 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 666 | 1572-1590 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 667 | 1766-1774 | Disease | denotes | COVID-19 | MESH:C000657245 |